Phase II study of alemtuzumab in chronic lymphoproliferative disorders

Alessandra Ferrajoli, Susan M. O'Brien, Jorge E. Cortes, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Razelle Kurzrock, Susan Lerner, Dimitrios P. Kontoyiannis, Michael J. Keating

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders. METHODS. Seventy-eight patients were enrolled. The most common diagnoses were chronic lymphocytic leukemia (n = 42 patients) and T-cell prolymphocytic leukemia (n = 18 patients). Before entering the study, the patients had received multiple therapies (median, three therapies) and the median time from diagnosis was 7 years. Alemtuzumab was given intravenously at doses of 3 mg, 10 mg, and 30 mg on 3 consecutive days, after which 30 mg was administered 3 times a week. Patients were treated for 4-12 weeks depending on disease response. All patients received prophylactic trimethoprim/sulfamethoxazole and valacyclovir. RESULTS. The overall response rate was 35%, the complete response (CR) rate was 13%, and the partial response (PR) rate was 22%. The median duration of response was 18 months for patients achieving a CR and 7 months for patients achieving a PR. The median duration of survival was 25 months for patients who had a response and 12 months for the entire population. Normalization of the lymphocyte count was observed in 84% of patients and resolution of bone marrow involvement was observed in 49% of patients. The most common infusion-related adverse events were fever, rigors, skin rash, nausea, and dyspnea. These were most common during the first week of therapy. Hematologic toxicity was comprised of long-lasting lymphocytopenia and transient neutropenia and thrombocytopenia. Thirty-six patients (46%) experienced at least one episode of fever or infection. CONCLUSIONS. Alemtuzumab has a high response rate in patients with chronic lymphoproliferative disorders.

Original languageEnglish (US)
Pages (from-to)773-778
Number of pages6
JournalCancer
Volume98
Issue number4
DOIs
StatePublished - Aug 15 2003
Externally publishedYes

Fingerprint

Lymphoproliferative Disorders
valacyclovir
alemtuzumab
Fever
T-Cell Prolymphocytic Leukemia
Lymphopenia
Sulfamethoxazole Drug Combination Trimethoprim
Lymphocyte Count
B-Cell Chronic Lymphocytic Leukemia
Exanthema
Neutropenia
Thrombocytopenia
Dyspnea
Nausea
Therapeutics

Keywords

  • Alemtuzumab
  • Chronic lymphocytic leukemia (CLL)
  • Infections
  • Lymphoproliferative disorders
  • Prolymphocytic leukemia (PLL)
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ferrajoli, A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Thomas, D. A., Faderl, S., ... Keating, M. J. (2003). Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer, 98(4), 773-778. https://doi.org/10.1002/cncr.11551

Phase II study of alemtuzumab in chronic lymphoproliferative disorders. / Ferrajoli, Alessandra; O'Brien, Susan M.; Cortes, Jorge E.; Giles, Francis J.; Thomas, Deborah A.; Faderl, Stefan; Kurzrock, Razelle; Lerner, Susan; Kontoyiannis, Dimitrios P.; Keating, Michael J.

In: Cancer, Vol. 98, No. 4, 15.08.2003, p. 773-778.

Research output: Contribution to journalArticle

Ferrajoli, A, O'Brien, SM, Cortes, JE, Giles, FJ, Thomas, DA, Faderl, S, Kurzrock, R, Lerner, S, Kontoyiannis, DP & Keating, MJ 2003, 'Phase II study of alemtuzumab in chronic lymphoproliferative disorders', Cancer, vol. 98, no. 4, pp. 773-778. https://doi.org/10.1002/cncr.11551
Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003 Aug 15;98(4):773-778. https://doi.org/10.1002/cncr.11551
Ferrajoli, Alessandra ; O'Brien, Susan M. ; Cortes, Jorge E. ; Giles, Francis J. ; Thomas, Deborah A. ; Faderl, Stefan ; Kurzrock, Razelle ; Lerner, Susan ; Kontoyiannis, Dimitrios P. ; Keating, Michael J. / Phase II study of alemtuzumab in chronic lymphoproliferative disorders. In: Cancer. 2003 ; Vol. 98, No. 4. pp. 773-778.
@article{bf8ca7e6b49b4a5781b01dae039397ff,
title = "Phase II study of alemtuzumab in chronic lymphoproliferative disorders",
abstract = "BACKGROUND. Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders. METHODS. Seventy-eight patients were enrolled. The most common diagnoses were chronic lymphocytic leukemia (n = 42 patients) and T-cell prolymphocytic leukemia (n = 18 patients). Before entering the study, the patients had received multiple therapies (median, three therapies) and the median time from diagnosis was 7 years. Alemtuzumab was given intravenously at doses of 3 mg, 10 mg, and 30 mg on 3 consecutive days, after which 30 mg was administered 3 times a week. Patients were treated for 4-12 weeks depending on disease response. All patients received prophylactic trimethoprim/sulfamethoxazole and valacyclovir. RESULTS. The overall response rate was 35{\%}, the complete response (CR) rate was 13{\%}, and the partial response (PR) rate was 22{\%}. The median duration of response was 18 months for patients achieving a CR and 7 months for patients achieving a PR. The median duration of survival was 25 months for patients who had a response and 12 months for the entire population. Normalization of the lymphocyte count was observed in 84{\%} of patients and resolution of bone marrow involvement was observed in 49{\%} of patients. The most common infusion-related adverse events were fever, rigors, skin rash, nausea, and dyspnea. These were most common during the first week of therapy. Hematologic toxicity was comprised of long-lasting lymphocytopenia and transient neutropenia and thrombocytopenia. Thirty-six patients (46{\%}) experienced at least one episode of fever or infection. CONCLUSIONS. Alemtuzumab has a high response rate in patients with chronic lymphoproliferative disorders.",
keywords = "Alemtuzumab, Chronic lymphocytic leukemia (CLL), Infections, Lymphoproliferative disorders, Prolymphocytic leukemia (PLL), Toxicity",
author = "Alessandra Ferrajoli and O'Brien, {Susan M.} and Cortes, {Jorge E.} and Giles, {Francis J.} and Thomas, {Deborah A.} and Stefan Faderl and Razelle Kurzrock and Susan Lerner and Kontoyiannis, {Dimitrios P.} and Keating, {Michael J.}",
year = "2003",
month = "8",
day = "15",
doi = "10.1002/cncr.11551",
language = "English (US)",
volume = "98",
pages = "773--778",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Phase II study of alemtuzumab in chronic lymphoproliferative disorders

AU - Ferrajoli, Alessandra

AU - O'Brien, Susan M.

AU - Cortes, Jorge E.

AU - Giles, Francis J.

AU - Thomas, Deborah A.

AU - Faderl, Stefan

AU - Kurzrock, Razelle

AU - Lerner, Susan

AU - Kontoyiannis, Dimitrios P.

AU - Keating, Michael J.

PY - 2003/8/15

Y1 - 2003/8/15

N2 - BACKGROUND. Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders. METHODS. Seventy-eight patients were enrolled. The most common diagnoses were chronic lymphocytic leukemia (n = 42 patients) and T-cell prolymphocytic leukemia (n = 18 patients). Before entering the study, the patients had received multiple therapies (median, three therapies) and the median time from diagnosis was 7 years. Alemtuzumab was given intravenously at doses of 3 mg, 10 mg, and 30 mg on 3 consecutive days, after which 30 mg was administered 3 times a week. Patients were treated for 4-12 weeks depending on disease response. All patients received prophylactic trimethoprim/sulfamethoxazole and valacyclovir. RESULTS. The overall response rate was 35%, the complete response (CR) rate was 13%, and the partial response (PR) rate was 22%. The median duration of response was 18 months for patients achieving a CR and 7 months for patients achieving a PR. The median duration of survival was 25 months for patients who had a response and 12 months for the entire population. Normalization of the lymphocyte count was observed in 84% of patients and resolution of bone marrow involvement was observed in 49% of patients. The most common infusion-related adverse events were fever, rigors, skin rash, nausea, and dyspnea. These were most common during the first week of therapy. Hematologic toxicity was comprised of long-lasting lymphocytopenia and transient neutropenia and thrombocytopenia. Thirty-six patients (46%) experienced at least one episode of fever or infection. CONCLUSIONS. Alemtuzumab has a high response rate in patients with chronic lymphoproliferative disorders.

AB - BACKGROUND. Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders. METHODS. Seventy-eight patients were enrolled. The most common diagnoses were chronic lymphocytic leukemia (n = 42 patients) and T-cell prolymphocytic leukemia (n = 18 patients). Before entering the study, the patients had received multiple therapies (median, three therapies) and the median time from diagnosis was 7 years. Alemtuzumab was given intravenously at doses of 3 mg, 10 mg, and 30 mg on 3 consecutive days, after which 30 mg was administered 3 times a week. Patients were treated for 4-12 weeks depending on disease response. All patients received prophylactic trimethoprim/sulfamethoxazole and valacyclovir. RESULTS. The overall response rate was 35%, the complete response (CR) rate was 13%, and the partial response (PR) rate was 22%. The median duration of response was 18 months for patients achieving a CR and 7 months for patients achieving a PR. The median duration of survival was 25 months for patients who had a response and 12 months for the entire population. Normalization of the lymphocyte count was observed in 84% of patients and resolution of bone marrow involvement was observed in 49% of patients. The most common infusion-related adverse events were fever, rigors, skin rash, nausea, and dyspnea. These were most common during the first week of therapy. Hematologic toxicity was comprised of long-lasting lymphocytopenia and transient neutropenia and thrombocytopenia. Thirty-six patients (46%) experienced at least one episode of fever or infection. CONCLUSIONS. Alemtuzumab has a high response rate in patients with chronic lymphoproliferative disorders.

KW - Alemtuzumab

KW - Chronic lymphocytic leukemia (CLL)

KW - Infections

KW - Lymphoproliferative disorders

KW - Prolymphocytic leukemia (PLL)

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0042071567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042071567&partnerID=8YFLogxK

U2 - 10.1002/cncr.11551

DO - 10.1002/cncr.11551

M3 - Article

C2 - 12910522

AN - SCOPUS:0042071567

VL - 98

SP - 773

EP - 778

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -